Researchers have published findings from the phase 2 LITESPARK-003 study of patients with previously untreated advanced clear ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

MRK posts encouraging Q4 results. However, the decision to temporarily halt shipments of Gardasil vaccines to China has ...

During a live event, Kathryn E. Beckermann, MD, PhD, discussed the treatment of RCC with insights from a recent trial on ...

Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 EPS, expectations were $1.85. Operator: Thank you for standing by. Welcome to ...

Merck, the giant pharmaceutical company with multiple facilities in eastern Pennsylvania and New Jersey, isn’t too enthused ...

The U.S. Food and Drug Administration (FDA) has granted priority review to the company's application for expanded use of its oral cancer drug, Welireg. If approved, this would make Welireg the ...

The team are now recruiting patients into a new trial called LITESPARK-022 that combines Keytruda with MSD’s HIF-2 inhibitor Welireg (belzutifan) as an adjuvant treatment for RCC. Welireg was ...

"We will continue to work closely with the authorities toward approval in the EU." Welireg generated $139 million in sales during 2024’s third quarter and is the only approved HIF-2α inhibitor ...

The company's blockbuster drug Keytruda contributed $29.48 billion in sales in 2024, but the first of its patent expirations begins in 2028.